Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 7:32 PM
Ignite Modification Date:
2025-12-24 @ 7:32 PM
NCT ID:
NCT03397303
Eligibility Criteria:
Inclusion Criteria:
* Male or female aged 18 to 65
* Having social insurance status
* Having given informed consent
* Diagnostic of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), CMT1a or Anti-MAG (peak immunoglobulin M (IGm)\>15,000 BTU)
Exclusion Criteria:
For controls:
* Person staying in a health or social facility
* Person unable to understand the protocol and to respect the modalities
* Person deprived of liberty
* Person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice)
* Participation in another biomedical research in progress
* Diabetes, history of neuromuscular disease
For CIDP:
* Person staying in a health or social facility
* Person unable to understand the protocol and to respect the modalities
* Person deprived of liberty
* Person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice)
* Participation in another biomedical research in progress
* MRC score \< 3
For Charcot-Marie-Tooth type 1 (CMT1) and anti-MAG:
* Person staying in a health or social facility
* Person unable to understand the protocol and to respect the modalities
* Person deprived of liberty
* Person of legal age benefiting from a system of legal protection (guardianship, curators or safeguard of justice)
* Participation in another biomedical research in progress
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
65 Years
Study:
NCT03397303
Study Brief:
Protocol Section:
NCT03397303